Zydus Lifesciences Limited has received final approval for Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA), as per an exchange filing.
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma.
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
The group now has 354 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Maharashtra Transport Department Launches Awareness Tableau For Tukaram Maharaj Palkhi Procession
₹122 Crore New India Co-operative Bank Scam: EOW Closes In On Key Accused Ajay Singh Rathore
Mumbai News: Govandi Housing Society Moves SHRC Against BMC Over Illegal Structural Modifications
Mumbai News: MIDC Police Bust Major Mephedrone Racket, Arrest 3 & Seize Drugs Worth ₹36.57 Lakh
